As part of the Inflation Reduction Act, Medicare will negotiate drug prices, limit annual price hikes and cap insulin costs paid by older Americans.
Author: Ken Alltucker, USA TODAY
FDA approves new drug lecanemab that appears to slow early, mild Alzheimer’s
Federal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.
Half of ambulance rides yield surprise medical bills. What’s being done to protect people?
No Surprises Act protects consumers from costly surprise bills during emergency medical care, but not from ambulance bills.
Here’s why private Medicare plans are set to pass traditional Medicare enrollment
More than 28 million older adults enrolled in Medicare plans administered by private insurance companies rather than the federal government.
Amid backlash, CDC’s new opioid guidance aims to curb addiction and treat patients
The CDC issued new guidance for doctors who treat pain patients that reverses a 2016 version that was used to sharply curtail opioid prescriptions.
‘Calm before the storm’: Health insurance costs set to spike after they stayed mostly flat in 2022, survey finds
Kaiser Family Foundation survey reports average cost for an employer-provided health increased just 1% this year.
Biden administration vows tougher oversight of poor-performing nursing homes with safety issues
The Biden administration will bolster oversight of poor-performing nursing homes with escalating fines and terminating federal funding.
More than 1.3M Americans ration life-saving insulin due to cost. That’s ‘very worrisome’ to doctors.
Doctors warn the high cost of insulin puts all type 1 and some type 2 diabetes patients at risk of medical complications, hospitalization and death.
Inflation is near a four-decade high. So why aren’t health care costs significantly higher?
For the first time in 40 years, inflation is rising faster than medical costs. But employers and health insurers are bracing for that to soon change.
Alzheimer’s drug slowed progression of disease in late-stage study, drugmakers say
Officials said they will submit the new trial results to the FDA to bolster its case that lecanemab should be approved as an Alzheimer’s treatment.